GreatWhip Announces Black Friday Event Offering CO2 Cylinders for Soda Manufacturing

“soda maker”

GreatWhip, a leading provider of CO2 cylinders for soda makers, is pleased to announce a special Black Friday sale with a 15% discount on all CO2 cylinders. This sale is the perfect opportunity to stock up on your favorite GreatWhip products and make your own delicious carbonated drinks at home.

The GreatWhip 60L Co2 cylinder is compatible with most standard soda maker machines and is filled with ultra-pure Co2, tested at 99.9%. It is also free of chemical taste or bad smell and is easily installed with any soda maker.

With each CO2 cylinder, you can make more than 60L of fizzy water, which is equivalent to 120 bottles of store-bought soda. This makes GreatWhip CO2 cylinders a cost-effective way to enjoy your favorite carbonated drinks.

Black Friday Sale Details

The Black Friday sale will run from 2023.11.08. To take advantage of the discount, simply use the code Greatwhip15 at checkout Get 15% OFF.

About GreatWhip

GreatWhip is a leading provider of CO2 cylinders for soda makers. The company is committed to providing customers with the highest quality products and services. GreatWhip CO2 cylinders are made with the finest materials and are backed by  satisfaction guarantee.

To learn more about GreatWhip and its products, please visit the company’s website at https://www.greatwhipshop.com/.

Media Contact
Company Name: GreatWhip
Contact Person: James
Email: Send Email
Phone: +86-13612982115
Country: China
Website: https://www.greatwhipshop.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: GreatWhip Announces Black Friday Event Offering CO2 Cylinders for Soda Manufacturing

Underwater Acoustic Communication Market Making Waves, Poised to Reach USD 3.5 Billion by 2028, at a CAGR of 11.0%

“Underwater Acoustic Communication Market”
The Underwater Acoustic Communication Market Size is expected to reach USD 3.5 billion by 2028 from USD 2.1 billion in 2023 growing at a CAGR of 11.0% during forecast year.

CHICAGO, Dec 04, 2023 – The global Underwater Acoustic Communication Market is experiencing substantial growth, with a current valuation of USD 2.1 billion in 2023 and an anticipated increase to USD 3.5 billion by 2028, reflecting a robust Compound Annual Growth Rate (CAGR) of 11.0% during the forecast period. These insights are detailed in a comprehensive report by MarketsandMarkets, a leading market research and consulting firm.

Applications like as offshore oil and gas development, environmental monitoring, defence and security, and marine research heavily rely on underwater acoustic communication technology. The growing need for dependable underwater communication solutions, developments in sonar technology, and the growing use of autonomous underwater vehicles (AUVs) for underwater exploration are the main drivers of the market’s anticipated expansion. The study analyses major competitors in the global underwater acoustic communication market and examines important market segments, growth factors, obstacles, and prospects.

• Informational PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=259232207

Key Segments:

Communication Range Segment: The Underwater Acoustic Communication market includes various communication ranges, such as short-range, medium-range, and long-range communication, catering to different underwater applications.

End-User Segment: The market serves various end users, including oil and gas companies, defense and security agencies, research institutions, and environmental monitoring organizations, each with specific requirements for underwater communication solutions.

Application Segment: Underwater acoustic communication finds applications in diverse sectors, including offshore oil and gas exploration, environmental monitoring, marine research, defense, and surveillance, reflecting the broad spectrum of underwater communication needs.

Browse 153 market data Tables and 52 Figures spread through 199 Pages and in-depth TOC on “Underwater Acoustic Communication Market by Interface Platform, Application, Communication Depth, End User and Region – Global Forecast to 2028”

View detailed Table of Content here – https://www.marketsandmarkets.com/Market-Reports/underwater-acoustic-communication-market-259232207.html

Underwater Acoustic Communication Market

Growth Drivers:

Increasing Offshore Activities: The growing demand for offshore oil and gas exploration and production activities drives the need for reliable and efficient underwater communication solutions.

Advancements in Sonar Technologies: Ongoing advancements in sonar technologies, including underwater acoustic modems and transducers, contribute to the improvement of underwater communication capabilities.

Rising Adoption of AUVs: The increasing adoption of autonomous underwater vehicles (AUVs) for underwater exploration and surveillance creates a demand for effective underwater communication systems.

Challenges:

Limited Data Transfer Rates: The limited data transfer rates in underwater environments pose challenges for real-time communication and data transmission.

Environmental Interference: Factors such as water temperature, salinity, and marine life can impact the performance of underwater acoustic communication systems, posing challenges for reliability.

Opportunities:

Underwater IoT Applications: The integration of underwater acoustic communication with the Internet of Things (IoT) opens opportunities for monitoring and collecting data from underwater sensors.

Marine Research and Exploration: The expansion of marine research and exploration activities, including deep-sea exploration, presents opportunities for the deployment of advanced underwater communication solutions.

Key Players:

The report identifies key players in the global Underwater Acoustic Communication market, including:

Teledyne Technologies Incorporated: A leading provider of underwater acoustic communication solutions, including modems and hydrophones for marine applications.

Kongsberg Gruppen: A multinational company specializing in underwater technology, offering acoustic modems, transceivers, and communication systems for marine and defense applications.

Thales Group: A global technology company providing underwater communication solutions for defense, marine, and offshore applications.

L3Harris Technologies, Inc.: A multinational aerospace and defense company offering communication and sonar solutions for underwater applications.

Sonardyne International Ltd.: A UK-based company specializing in underwater technology, providing acoustic communication and positioning solutions for marine and subsea industries.

The growing need for dependable communication solutions in underwater environments is expected to propel significant growth in the global underwater acoustic communication market. Underwater acoustic communication systems are anticipated to be essential to many different applications, including environmental monitoring and offshore exploration, as technology develops.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/underwater-acoustic-communication-market-259232207.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Underwater Acoustic Communication Market Making Waves, Poised to Reach USD 3.5 Billion by 2028, at a CAGR of 11.0%

Renal Cell Carcinoma Pipeline, FDA Approvals, Clinical Trials Developments, Companies 2023 | AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, and others.

DelveInsight’s, “Renal Cell Carcinoma Pipeline Insight 2023” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Renal Cell Carcinoma pipeline landscape. It covers the Renal Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Renal Cell Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Renal Cell Carcinoma Pipeline Report

  • DelveInsight’s Renal Cell Carcinoma pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Renal Cell Carcinoma treatment.
  • The leading companies working in the Renal Cell Carcinoma Market include AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc., X4 pharmaceuticals, and others.
  • Promising Renal Cell Carcinoma Pipeline Therapies in the various stages of development include Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab, lenvatinib, everolimus, and others.
  • November 2023: AVEO Pharmaceuticals Inc. announced a study of Phase 3 clinical trials for Tivozanib and Nivolumab. This study will be comparing tivozanib in combination with nivolumab to tivozanib alone in subjects with advanced Renal Cell Carcinoma (RCC) who have had 1 or 2 prior lines of therapy, one of which was an Immune Checkpoint Inhibitor (ICI).
  • November 2023: Bristol-Myers Squibb announced a study of Phase 3 clinical trials for Nivolumab and Ipilimumab. The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal Cell Cancer.

 

Request a sample and discover the recent advances in Renal Cell Carcinoma Treatment Drugs @ Renal Cell Carcinoma Pipeline Report

 

In the Renal Cell Carcinoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Renal Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Renal Cell Carcinoma Overview

Renal cell carcinoma (RCC) is also called hypernephroma, renal adenocarcinoma, or renal or kidney cancer. Renal cell cancer is a disease in which malignant (cancer) cells form in tubules of the kidney. In early stages Renal carcinoma is symptom free but as the diseases progresses the symptoms may include: lump in the abdomen, fatigue, and unexplained weight loss, blood in the urine, loss of appetite, vision problem, and excessive hair growth.

 

Find out more about Renal Cell Carcinoma Treatment Landscape @ Drugs for Renal Cell Carcinoma Treatment

 

Renal Cell Carcinoma Emerging Drugs Profile

  • CM082: Betta Pharmaceuticals
  • TQB 2450: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • IPI-549: Infinity Pharmaceuticals
  • CMN-001: ColImmune

 

Renal Cell Carcinoma Pipeline Therapeutics Assessment

There are approx. 30+ key companies which are developing the therapies for Renal Cell Carcinoma. The Renal Cell Carcinoma companies which have their Renal Cell Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Betta Pharmaceuticals.

 

DelveInsight’s Renal Cell Carcinoma pipeline report covers around 30+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Subcutaneous
  • Intravenous
  • Intramuscular
  • Molecule Type

 

Products have been categorized under various Molecule types such as

  • Bispecific Antibody
  • Peptides
  • Small molecule
  • Gene therapy
  • Product Type

 

Learn more about the emerging Renal Cell Carcinoma Pipeline Therapies @ Renal Cell Carcinoma Clinical Trials Assessment

 

Scope of the Renal Cell Carcinoma Pipeline Report

  • Coverage- Global
  • Renal Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Renal Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Renal Cell Carcinoma Companies- AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc., X4 pharmaceuticals, and others.
  • Renal Cell Carcinoma Pipeline Therapies- Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab, lenvatinib, everolimus, and others.

 

Dive deep into rich insights for new drugs for Renal Cell Carcinoma treatment, Visit @ Renal Cell Carcinoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Renal Cell Carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Renal Cell Carcinoma – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Renal Cell Carcinoma Collaboration Deals
  9. Late Stage Products (Phase III)
  10. TQB 2450: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. IPI-549: Infinity Pharmaceuticals
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. AVB-S6-500: Aravive Inc.
  17. Drug profiles in the detailed report…..
  18. Preclinical Stage Products
  19. Drug Name: Company name
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Renal Cell Carcinoma Key Companies
  23. Renal Cell Carcinoma Key Products
  24. Renal Cell Carcinoma – Unmet Needs
  25. Renal Cell Carcinoma – Market Drivers and Barriers
  26. Renal Cell Carcinoma – Future Perspectives and Conclusion
  27. Renal Cell Carcinoma Analyst Views
  28. Renal Cell Carcinoma Key Companies
  29. Appendix

 

For further information on the Renal Cell Carcinoma pipeline therapeutics, reach out @ Renal Cell Carcinoma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/radiation-induced-esophagitis-market-forecast

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Renal Cell Carcinoma Pipeline, FDA Approvals, Clinical Trials Developments, Companies 2023 | AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, and others.

Small Lymphocytic Lymphoma Pipeline, FDA Approvals, Clinical Trials Developments, Companies 2023 | Loxo Oncology, Chia Tai Tianqing Pharmaceutical Group, Iovance Biotherapeutics, and others.

DelveInsight’s, “Small Lymphocytic Lymphoma Pipeline Insight 2023” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Small Lymphocytic Lymphoma pipeline landscape. It covers the Small Lymphocytic Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Small Lymphocytic Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Small Lymphocytic Lymphoma Pipeline Report

  • DelveInsight’s Small Lymphocytic Lymphoma Pipeline analysis depicts a robust space with 80+ active players working to develop 80+ pipeline treatment therapies.
  • The leading Small Lymphocytic Lymphoma Companies working in the market include Loxo Oncology, Chia Tai Tianqing Pharmaceutical Group, Iovance Biotherapeutics, Ascentage Pharma, NovalGen, Pfizer, MingSight Pharmaceuticals, Jiangsu MingSight-Relin Pharmaceutical, TG Therapeutics, and others
  • Promising Small Lymphocytic Lymphoma Pipeline Therapies in the various stages of the development include Pirtobrutinib, Bendamustine, Rituximab, Venetoclax, LOXO-305, ABT-199, ofatumumab, TG02 citrate, and others.
  • November 2023: AbbVie announced a study of Phase 2 clinical trials for Venetoclax and Obinutuzumab. A Multicenter, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Venetoclax-Obinutuzumab Retreatment in Patients With Recurring Chronic Lymphocytic Leukemia.
  • November 2023: Loxo Oncology Inc. announced a study of Phase 3 clinical trials for LOXO-305 and Idelalisib. This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who have previously received treatment with at least a BTK inhibitor. The main purpose is to compare LOXO-305 to idelalisib plus rituximab or bendamustine plus rituximab. Participation could last up to four years, and possibly longer, if the disease does not progress.
  • November 2023: AstraZeneca announced a study of Phase 3 clinical trials for Acalabrutinib. This is a global, Phase IIIb, multicenter, open-label, single-arm study to evaluate the safety and efficacy of acalabrutinib 100 mg twice daily (bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be enrolled into 3 following cohorts: treatment-naive (TN), relapsed/refractory (R/R), and prior ibrutinib therapy. For this study, participants in the UK will be enrolled ONLY into the R/R cohort or the prior ibrutinib cohort. Participants in the US will be enrolled ONLY into the TN or R/R cohort.

 

Request a sample and discover the recent advances in Small Lymphocytic Lymphoma Treatment Drugs @ Small Lymphocytic Lymphoma Pipeline Report

 

In the Small Lymphocytic Lymphoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Small Lymphocytic Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Small Lymphocytic Lymphoma Overview

Small Lymphocytic Lymphoma is an indolent (slow growing) non-Hodgkin lymphoma that affects B cells. B cells (also known as B lymphocytes) are specialized white blood cells. Under normal conditions they produce immunoglobulins (also called antibodies) that help protect our bodies against infection and disease. Small lymphocytic lymphoma is considered part of the same disease process as CLL; however, the disease is known as SLL when it involves a lymph node, and CLL when it involves the peripheral blood.

 

Find out more about Small Lymphocytic Lymphoma Treatment Landscape @ Drugs for Small Lymphocytic Lymphoma Treatment

 

Small Lymphocytic Lymphoma Emerging Drugs Profile

  • TQ-B3525: Chia Tai Tianqing Pharmaceutical Group
  • LOXO-305: Loxo Oncology
  • IOV 2001: Iovance Biotherapeutics

 

Small Lymphocytic Lymphoma Pipeline Therapeutics Assessment

There are approx. 80+ key companies which are developing the therapies for Small Lymphocytic Lymphoma. The Small Lymphocytic Lymphoma companies which have their Small Lymphocytic Lymphoma drug candidates in the most advanced stage, i.e. phase III include, Loxo Oncology.

 

DelveInsight’s Small Lymphocytic Lymphoma pipeline report covers around 80+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Small Lymphocytic Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Small Lymphocytic Lymphoma Pipeline Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Learn more about the emerging Small Lymphocytic Lymphoma Pipeline Therapies @ Small Lymphocytic Lymphoma Clinical Trials Assessment

 

Scope of the Small Lymphocytic Lymphoma Pipeline Report

  • Coverage- Global
  • Small Lymphocytic Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Small Lymphocytic Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Small Lymphocytic Lymphoma Companies- Loxo Oncology, Chia Tai Tianqing Pharmaceutical Group, Iovance Biotherapeutics, Ascentage Pharma, NovalGen, Pfizer, MingSight Pharmaceuticals, Jiangsu MingSight-Relin Pharmaceutical, TG Therapeutics, and others
  • Small Lymphocytic Lymphoma Pipeline Therapies- Pirtobrutinib, Bendamustine, Rituximab, Venetoclax, LOXO-305, ABT-199, ofatumumab, TG02 citrate, and others.

 

Dive deep into rich insights for new drugs for Small Lymphocytic Lymphoma treatment, Visit @ Small Lymphocytic Lymphoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Small Lymphocytic Lymphoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Small Lymphocytic Lymphoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Pre-Registration)
  8. Drug Name : Company Name
  9. Drug profiles in the detailed report…..
  10. Last Stage Products (Phase III)
  11. LOXO-305: Loxo Oncology
  12. Drug profiles in the detailed report…..
  13. Mid Stage Products (Phase I/II)
  14. TQ-B3525: Chia Tai Tianqing Pharmaceutical Group
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name : Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Small Lymphocytic Lymphoma Key Companies
  21. Small Lymphocytic Lymphoma Key Products
  22. Small Lymphocytic Lymphoma – Unmet Needs
  23. Small Lymphocytic Lymphoma – Market Drivers and Barriers
  24. Small Lymphocytic Lymphoma – Future Perspectives and Conclusion
  25. Small Lymphocytic Lymphoma Analyst Views
  26. Small Lymphocytic Lymphoma Key Companies
  27. Appendix

 

For further information on the Small Lymphocytic Lymphoma pipeline therapeutics, reach out @ Small Lymphocytic Lymphoma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/primary-ciliary-dyskinesia-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Small Lymphocytic Lymphoma Pipeline, FDA Approvals, Clinical Trials Developments, Companies 2023 | Loxo Oncology, Chia Tai Tianqing Pharmaceutical Group, Iovance Biotherapeutics, and others.

Soft Tissue Sarcoma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 | Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, and others.

DelveInsight’s, “Soft Tissue Sarcoma Pipeline Insight, 2023,” report provides comprehensive insights about 125+ companies and 130+ pipeline drugs in Soft Tissue Sarcoma pipeline landscape. It covers the Soft Tissue Sarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Soft Tissue Sarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Soft Tissue Sarcoma Pipeline Report

  • DelveInsight’s Soft Tissue Sarcoma pipeline report depicts a robust space with 125+ active players working to develop 130+ pipeline therapies for Soft Tissue Sarcoma treatment.
  • The leading companies working in the Soft Tissue Sarcoma Market include Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and others.
  • Promising Soft Tissue Sarcoma Pipeline Therapies in the various stages of development include Olaratumab, Pembrolizumab, NBTXR3, Glufosfamide, PXD101, Doxorubicin, and others.
  • December 2023: Epizyme Inc. announced a study of Phase 3 clinical trials for Tazemetostat and Doxorubicin HCl. The open-label phase 1b portion is designed to evaluate the safety of the combination of tazemetostat + doxorubicin, as well as to establish the maximum tolerated dose (MTD) and the RP3D. The phase 3 portion of the clinical trial aims to compare tazemetostat + doxorubicin to the current front-line standard treatment, single-agent doxorubicin + placebo, when used as first-line treatment in locally advanced unresectable or metastatic ES.
  • November 2023: Lytix Biopharma AS announced a study of Phase 2 clinical trials for LTX-315 and TILs. An Open Label Phase II Single Centre Study Investigating the Safety and Efficacy of LTX-315 and Adoptive T-cell Therapy in Patients With Advanced/Metastatic Soft Tissue Sarcoma (ATLAS-IT-04).

 

Request a sample and discover the recent advances in Soft Tissue Sarcoma Treatment Drugs @ Soft Tissue Sarcoma Pipeline Outlook Report

 

In the Soft Tissue Sarcoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Soft Tissue Sarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Soft Tissue Sarcoma Overview

Soft tissue sarcoma is a disease in which malignant (cancer) cells form in the soft tissues of the body. Having certain inherited disorders can increase the risk of soft tissue sarcoma. A sign of soft tissue sarcoma is a lump or swelling in soft tissue of the body. Soft tissue sarcoma is diagnosed with a biopsy.

 

Find out more about Soft Tissue Sarcoma Treatment Landscape @ Drugs for Soft Tissue Sarcoma Treatment

 

Soft Tissue Sarcoma Emerging Drugs Profile

  • AL3818: Advenchen Laboratories
  • L19 TNF: Philogen
  • Camsirubicin: Monopar Therapeutics

 

Soft Tissue Sarcoma Pipeline Therapeutics Assessment

There are approx. 125+ key companies which are developing the therapies for Soft Tissue Sarcoma. The Soft Tissue Sarcoma companies which have their Soft Tissue Sarcoma drug candidates in the most advanced stage, i.e. phase III include, Advenchen Laboratories, LLC.

 

DelveInsight’s Soft Tissue Sarcoma pipeline report covers around 130+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Soft Tissue Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.

 

Soft Tissue Sarcoma Pipeline Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Learn more about the emerging Soft Tissue Sarcoma Pipeline Therapies @ Soft Tissue Sarcoma Clinical Trials Assessment

 

Scope of the Soft Tissue Sarcoma Pipeline Report

  • Coverage- Global
  • Soft Tissue Sarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Soft Tissue Sarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Soft Tissue Sarcoma Companies- Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and others.
  • Soft Tissue Sarcoma Pipeline Therapies- Olaratumab, Pembrolizumab, NBTXR3, Glufosfamide, PXD101, Doxorubicin, and others.

 

Dive deep into rich insights for new drugs for Soft Tissue Sarcoma treatment, Visit @ Soft Tissue Sarcoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Soft Tissue Sarcoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Soft Tissue Sarcoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Anlotinib: Advenchen Laboratories, LLC
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Camsirubicin: Monopar Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. FHD-609: Foghorn Therapeutics
  15. Drug profiles in the detailed report…..
  16. Inactive Products
  17. Soft Tissue Sarcoma Key Companies
  18. Soft Tissue Sarcoma Key Products
  19. Soft Tissue Sarcoma- Unmet Needs
  20. Soft Tissue Sarcoma- Market Drivers and Barriers
  21. Soft Tissue Sarcoma- Future Perspectives and Conclusion
  22. Soft Tissue Sarcoma Analyst Views
  23. Soft Tissue Sarcoma Key Companies
  24. Appendix

 

For further information on the Soft Tissue Sarcoma Pipeline Therapeutics, reach out @ Soft Tissue Sarcoma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/peripheral-nerve-repair-devices-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Soft Tissue Sarcoma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 | Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, and others.

Triple Negative Breast Cancer Pipeline, FDA Approvals, Clinical Trials Assessment, Companies 2023 | Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., and others.

DelveInsight’s, “Triple Negative Breast Cancer Pipeline Insight 2023” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Triple Negative Breast Cancer pipeline landscape. It covers the Triple Negative Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Triple Negative Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Triple Negative Breast Cancer Pipeline Report

  • DelveInsight’s Triple Negative Breast Cancer Pipeline analysis depicts a robust space with 75+ active players working to develop 80+ pipeline treatment therapies.
  • The leading Triple Negative Breast Cancer Companies working in the market include Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others.
  • Promising Triple Negative Breast Cancer Pipeline Therapies in the various stages of development include Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Taxotere® (100 mg/m2), B013+Nab-Paclitaxel, ZEN003694, Talazoparib, Pembrolizumab, Sacituzumab Govitecan-hziy, Datopotamab Deruxtecan (Dato-DXd), and others.
  • November 2023: Shanghai Jiaolian Drug Research and Development Co., Ltd announced a study of Phase 2 & 3 clinical trials for B013+Nab-Paclitaxel. This Phase II/III study assessed the efficacy, safety, pharmacokinetics, and immunogenicity of B013 administered with nab-paclitaxel in participants with locally advanced or metastatic triple negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC).
  • November 2023: Gilead Sciences announced a study of Phase 3 clinical trials for Pembrolizumab. The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician’s choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
  • November 2023: AstraZeneca announced a study of Phase 1 & 2 clinical trials for Datopotamab Deruxtecan (Dato-DXd). This is a Phase 1/Phase 2, multicentre, open-label, multiple-cohort study, which is designed to evaluate the efficacy, safety, Pharmacokinetic, and immunogenicity of Dato-DXd in adult Chinese participants with advanced or metastatic solid tumours. It is a single-arm study with no blinding.
  • On June 2023, Shanghai Jiaolian Drug Research and Development Co., Ltd announced a study of phase 2 & 3 clinical trials for B013+Nab-Paclitaxel. This Phase II/III study assessed the efficacy, safety, pharmacokinetics, and immunogenicity of B013 administered with nab-paclitaxel in participants with locally advanced or metastatic triple negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC).
  • On February 2023, Jina Pharmaceuticals announced a study of phase 3 clinical trials for Taxotere® (100 mg/m2). The trial will be conducted as per the ICH GCP Guidelines E6 (R1), Schedule Y (Amended Version 2013), Declaration of Helsinki (Fortaleza, Brazil, October 2013), ICMR Guidelines for Biomedical Research on Human subjects and in accordance with other applicable guidelines.

 

Request a sample and discover the recent advances in Triple Negative Breast Cancer Treatment Drugs @ Triple Negative Breast Cancer Infection Pipeline Report

 

In the Triple Negative Breast Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Triple Negative Breast Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Triple Negative Breast Cancer Overview

Triple Negative Breast Cancer (TNBC) is defined as a tumor where the estrogen and progesterone (ER/PR) are negative, as assessed by immunohistochemistry (IHC), and there is a lack of overexpression of HER2, as assessed by immunohistochemistry (IHC), or the absence of its gene amplification, as assessed by fluorescence in situ hybridization technique. The epidemiological risk factor profiles also vary between TNBC (ER-PR-HER2-) and other breast cancers.

 

Find out more about Triple Negative Breast Cancer Treatment Landscape @ Drugs for Triple Negative Breast Cancer Treatment

 

Triple Negative Breast Cancer Emerging Drugs Profile

  • Camrelizumab: Jiangsu HengRui Medicine
  • IPI-549: Infinity Pharmaceuticals
  • PMD-026: Phoenix Molecular Designs

 

Triple Negative Breast Cancer Pipeline Therapeutics Assessment  

There are approx. 75+ key companies which are developing the therapies for Triple Negative Breast Cancer. The Triple Negative Breast Cancer companies which have their Triple Negative Breast Cancer drug candidates in the most advanced stage, i.e. phase III include, Jiangsu HengRui Medicine.

 

DelveInsight’s Triple Negative Breast Cancer pipeline report covers around 80+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Triple Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • intravenous
  • Subcutaneous
  • Topical.

 

Triple Negative Breast Cancer Pipeline Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Learn more about the emerging Triple Negative Breast Cancer Pipeline Therapies @ Triple Negative Breast Cancer Clinical Trials Assessment

 

Scope of the Triple Negative Breast Cancer Pipeline Report

  • Coverage- Global
  • Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Triple Negative Breast Cancer Companies- Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others.
  • Triple Negative Breast Cancer Pipeline Therapies- Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Taxotere® (100 mg/m2), B013+Nab-Paclitaxel, ZEN003694, Talazoparib, Pembrolizumab, Sacituzumab Govitecan-hziy, Datopotamab Deruxtecan (Dato-DXd), and others.

 

Dive deep into rich insights for new drugs for Triple Negative Breast Cancer treatment, Visit @ Triple Negative Breast Cancer Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Triple Negative Breast Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Triple Negative Breast Cancer – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Camrelizumab: Jiangsu HengRui Medicine
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. IPI-549: Infinity Pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. PMD-026: Phoenix Molecular Designs
  15. Drug profiles in the detailed report…..
  16. Inactive Products
  17. Triple Negative Breast Cancer Key Companies
  18. Triple Negative Breast Cancer Key Products
  19. Triple Negative Breast Cancer- Unmet Needs
  20. Triple Negative Breast Cancer- Market Drivers and Barriers
  21. Triple Negative Breast Cancer- Future Perspectives and Conclusion
  22. Triple Negative Breast Cancer Analyst Views
  23. Triple Negative Breast Cancer Key Companies
  24. Appendix

 

For further information on the Triple Negative Breast Cancer pipeline therapeutics, reach out @ Triple Negative Breast Cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/oral-electrolyte-solutions-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Triple Negative Breast Cancer Pipeline, FDA Approvals, Clinical Trials Assessment, Companies 2023 | Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., and others.

Chronic Kidney Disease Pipeline, FDA Approvals, Clinical Trials Developments, Companies 2023 | Boehringer Ingelheim, Eli Lilly and Company, Reata Pharmaceuticals, Novo Nordisk, Prokidney, and others.

DelveInsight’s, “Chronic Kidney Disease Pipeline Insights 2023” report provides comprehensive insights about 76+ companies and 80+ pipeline drugs in the Chronic Kidney Disease pipeline landscape. It covers the Chronic Kidney Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Kidney Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Chronic Kidney Disease Pipeline Report

  • DelveInsight’s Chronic Kidney Disease pipeline report depicts a robust space with 76+ active players working to develop 80+ pipeline therapies for Chronic Kidney Disease treatment.
  • The leading companies working in the Chronic Kidney Disease market include Boehringer Ingelheim, Eli Lilly and Company, Reata Pharmaceuticals, Novo Nordisk, Prokidney, KBP Biosciences, DiaMedica Therapeutics, Kibow Pharma, AstraZeneca, XORTX Therapeutics, Ionis Pharmaceuticals, Merck Sharp & Dohme, Disc Medicine, Roche, CinCor Pharma, Galapagos NV, Bayer, Sentien Biotechnologies, Inc., MISSION Therapeutics, AceLink Therapeutics, and others.
  • Promising Chronic Kidney Disease Pipeline Therapies in the various stages of development roxadustat, Monofer®, AZD5718, Dapagliflozin 10 mg, MEDI8367, AST-120, and others.
  • September 2023: Prokidney announced a study of phase 3 clinical trials for Renal Autologous Cell Therapy (REACT). The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with T2DM and CKD.
  • September 2023: Bayer announced a study of phase 3 clinical trials for Finerenone (BAY94-8862). The participants will take finerenone or a placebo once a day as tablets by mouth. All of the participants will also continue to take their current medicine for their CKD. The participants will be in the trial for up to about 50 months.

 

Request a sample and discover the recent advances in Chronic Kidney Disease Treatment Drugs @ Chronic Kidney Disease Pipeline Report

 

In the Chronic Kidney Disease pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Kidney Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Chronic Kidney Disease Overview

Chronic Kidney Disease is a condition in which kidneys are damaged and cannot filter blood. As a result, extra fluid and waste from the blood remain in the body, potentially leading to various health issues like heart disease and stroke. Chronic Kidney Disease has various levels of seriousness. It usually gets worse with time though treatment has been shown to slow progression. If left untreated, CKD can progress to kidney failure and early cardiovascular disease.

 

Find out more about Chronic Kidney Disease Therapeutics Assessment @ Chronic Kidney Disease Preclinical and Discovery Stage Products

 

Chronic Kidney Disease Emerging Drugs Profile

  • KBP-5074: KBP Biosciences
  • Ziltivekimab: Novo Nordisk
  • US-APR2020: Kibow Pharma
  • DM199: DiaMedica Therapeutics
  • AL-01211: AceLink Therapeutics

 

Chronic Kidney Disease Pipeline Therapeutics Assessment

There are approx. 76+ key companies which are developing the Chronic Kidney Disease therapies. The Chronic Kidney Disease companies which have their Chronic Kidney Disease drug candidates in the most advanced stage, i.e. phase III include, KBP Biosciences.

 

DelveInsight’s Chronic Kidney Disease Pipeline Report covers around 80+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Chronic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Chronic Kidney Disease Pipeline Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Learn more about the emerging Chronic Kidney Disease Pipeline Therapies @ Chronic Kidney Disease Clinical Trials Assessment

 

Scope of the Chronic Kidney Disease Pipeline Report

  • Coverage- Global
  • Chronic Kidney Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Chronic Kidney Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Chronic Kidney Disease Companies- Boehringer Ingelheim, Eli Lilly and Company, Reata Pharmaceuticals, Novo Nordisk, Prokidney, KBP Biosciences, DiaMedica Therapeutics, Kibow Pharma, AstraZeneca, XORTX Therapeutics, Ionis Pharmaceuticals, Merck Sharp & Dohme, Disc Medicine, Roche, CinCor Pharma, Galapagos NV, Bayer, Sentien Biotechnologies, Inc., MISSION Therapeutics, AceLink Therapeutics, and others.
  • Chronic Kidney Disease Pipeline Therapies- Roxadustat, Monofer®, AZD5718, Dapagliflozin 10 mg, MEDI8367, AST-120, and others.

 

Dive deep into rich insights for new drugs for Chronic Kidney Disease Treatment, Visit @ Chronic Kidney Disease Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Chronic Kidney Disease: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Chronic Kidney Disease– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. KBP-5074: KBP Biosciences
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. DM199: DiaMedica Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. AL-01211: AceLink Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. SCO-116: Scohia Pharma
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Chronic Kidney Disease Key Companies
  21. Chronic Kidney Disease Key Products
  22. Chronic Kidney Disease- Unmet Needs
  23. Chronic Kidney Disease- Market Drivers and Barriers
  24. Chronic Kidney Disease- Future Perspectives and Conclusion
  25. Chronic Kidney Disease Analyst Views
  26. Chronic Kidney Disease Key Companies
  27. Appendix

 

For further information on the Chronic Kidney Disease Pipeline therapeutics, reach out to Chronic Kidney Disease Unmet Needs and Analyst Views

 

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Kidney Disease Pipeline, FDA Approvals, Clinical Trials Developments, Companies 2023 | Boehringer Ingelheim, Eli Lilly and Company, Reata Pharmaceuticals, Novo Nordisk, Prokidney, and others.

Psoriasis Pipeline, FDA Approvals, Clinical Trials Development, and Companies 2023 | Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma

DelveInsight’s, “Psoriasis Pipeline Insight 2023” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Psoriasis pipeline landscape. It covers the Psoriasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Psoriasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Psoriasis Pipeline Report

  • DelveInsight’s Psoriasis pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Psoriasis treatment.
  • The leading companies working in the Psoriasis Market include Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals, and others.
  • Promising Psoriasis Pipeline Therapies in the various stages of development include GN-037, Clobetasol 17-propionate, Humira (Adalimumab), SB5 (Adalimumab Biosimilar), MP1032, KX01 0.01% (0.1 mg/g), and others.
  • October 2023: Mylan Pharmaceuticals Inc. announced a study of Phase 3 clinical trials for Humira 40 MG in Prefilled Syringe. A Multicenter, Randomized, Blinded, Parallel Group, Interchangeability Study in Moderate to Severe Chronic Plaque Psoriasis Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity Between Subjects Receiving Humira® Pre Filled Syringe (40 mg) Continuously and Subjects Undergoing Repeated Switches Between Humira® Pre Filled Syringe (40 mg) and Hulio Pre-filled Syringe (40 mg).
  • September 2023: Bristol-Myers Squibb announced a study of Phase 3 clinical trials for BMS-986165. The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have been previously enrolled in an applicable Phase 3 psoriasis study.

 

Request a sample and discover the recent advances in Psoriasis Treatment Drugs @ Psoriasis Infection Pipeline Outlook Report

 

In the Psoriasis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Psoriasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Psoriasis Overview

Psoriasis is a chronic inflammatory skin disorder that is accompanied with various clinical manifestations and is caused due to the involvement of genetic, environmental, and immunological factors. It is a non-contagious dermatosis disease affecting almost 2% of the world population. The percentage of body affected by psoriasis can vary on an individual basis.

 

Find out more about Psoriasis Treatment Landscape @ Drugs for Psoriasis Treatment

 

Psoriasis Emerging Drugs Profile

  • Topical roflumilast: Arcutis Biotherapeutics
  • GSK2982772: GlaxoSmithKline

 

Psoriasis Pipeline Therapeutics Assessment

There are approx. 80+ key companies which are developing the therapies for Psoriasis. The Psoriasis companies which have their Psoriasis drug candidates in the most advanced stage, i.e. Registered include, Biocad.

 

DelveInsight’s Psoriasis pipeline report covers around 80+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

The Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical.
  • Molecule Type

 

Psoriasis Pipeline Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Learn more about the emerging Psoriasis Pipeline Therapies @ Psoriasis Clinical Trials Assessment

 

Scope of the Psoriasis Pipeline Report

  • Coverage- Global
  • Psoriasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Psoriasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Psoriasis Companies- Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals, and others.
  • Psoriasis Pipeline Therapies- GN-037, Clobetasol 17-propionate, Humira (Adalimumab), SB5 (Adalimumab Biosimilar), MP1032, KX01 0.01% (0.1 mg/g), and others.

 

Dive deep into rich insights for new drugs for Psoriasis treatment, Visit @ Psoriasis Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Psoriasis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Psoriasis – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Psoriasis Collaboration Deals
  9. Late Stage Products (Phase III)
  10. CT-P43: Celltrion
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. EDP1815: Evelo Biosciences
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. AZD0284: AstraZeneca
  17. Drug profiles in the detailed report…..
  18. Early Stage Products (Preclinical)
  19. AZD0284: AstraZeneca
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Psoriasis Key Companies
  23. Psoriasis Key Products
  24. Psoriasis- Unmet Needs
  25. Psoriasis- Market Drivers and Barriers
  26. Psoriasis- Future Perspectives and Conclusion
  27. Psoriasis Analyst Views
  28. Psoriasis Key Companies
  29. Appendix

 

For further information on the Psoriasis pipeline therapeutics, reach out @ Psoriasis Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/kawasaki-disease-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Psoriasis Pipeline, FDA Approvals, Clinical Trials Development, and Companies 2023 | Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma

Refractory Multiple Myeloma Pipeline, FDA Approvals, Clinical Trials Development, Companies 2023 | NexImmune, Amgen, AbbVie, Allogene Therapeutics, Precision Biosciences, Takeda, and others.

DelveInsight’s, “Refractory Multiple Myeloma Pipeline Insight, 2023,” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Refractory Multiple Myeloma pipeline landscape. It covers the Refractory Multiple Myeloma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Refractory Multiple Myeloma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Refractory Multiple Myeloma Pipeline Report

  • DelveInsight’s Refractory Multiple Myeloma pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Refractory Multiple Myeloma treatment.
  • The leading companies working in the Refractory Multiple Myeloma Market include NexImmune, Amgen, AbbVie, Allogene Therapeutics, Precision Biosciences, Takeda Oncology, ORIC Pharmaceuticals, Ionis Pharmaceuticals, Cellectis S.A., YZY Biopharma, Janssen Research & Development, Bristol Myers Squibb, Lava Therapeutics, Prelude Therapeutics, and others.
  • Promising Refractory Multiple Myeloma Pipeline Therapies in the various stages of development include Venetoclax, Dexamethasone, Carfilzomib, Elotuzumab, Thalidomide, Cyclophosphamide, and others.
  • December 2023: Regeneron Pharmaceuticals announced a study of Phase 3 clinical trials for Linvoseltamab, Elotuzumab, Pomalidomide and Dexamethasone. This study is focused on participants who have multiple myeloma that has returned or needs to be treated again after one to four prior treatments and have standard cancer treatment options available to them. The aim of the study is to see how safe and effective linvoseltamab is compared to a combination of three cancer drugs: elotuzumab, pomalidomide and dexamethasone (called “EPd” in this form), one of these standard treatment options. Half of the participants in this study will get linvoseltamab, and the other half will get EPd. Both linvoseltamab and EPd will be referred to as “study drugs” in this form.
  • December 2023: Hoffmann-La Roche announced a study of Phase 1 clinical trials for Forimtamig, Carfilzomib, and Daratumumab. The purpose of this study is to evaluate the safety, tolerability, and preliminary anti-tumor activity of forimtamig when administered alone or in combination with carfilzomib or daratumumab or other combination partners in participants with relapsed or refractory multiple myeloma (r/r MM). The study consists of two phases: a dose exploration phase and a dose-expansion phase.
  • December 2023: Bristol-Myers Squibb announced a study of Phase 3 clinical trials for Mezigdomide, Carfilzomib, and Dexamethasone. The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.

 

Request a sample and discover the recent advances in Refractory Multiple Myeloma Treatment Drugs @ Refractory Multiple Myeloma Infection Pipeline Report

 

In the Refractory Multiple Myeloma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Refractory Multiple Myeloma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Refractory Multiple Myeloma Overview

Multiple myeloma is a cancer that starts in a type of white blood cell called a plasma cell. It’s relatively rare, making up less than 2 percent, but it’s the most common type of plasma cell tumor, according to the CDC. The survival rate of multiple myeloma has improved in recent years, but initial treatment still isn’t effective at completely getting rid of the cancer in the vast majority.

 

Find out more about Refractory Multiple Myeloma Treatment Drugs @ Drugs for Refractory Multiple Myeloma Treatment

 

Refractory Multiple Myeloma Emerging Drugs Profile

  • NEXI 002: NexImmune
  • AMG-701: Amgen
  • ABBV 453: AbbVie

 

Refractory Multiple Myeloma Pipeline Therapeutics Assessment

There are approx. 80+ key companies which are developing the therapies for Refractory Multiple Myeloma. The Refractory Multiple Myeloma companies which have their Refractory Multiple Myeloma drug candidates in the most advanced stage, i.e. Phase I/II include, NexImmune.

 

DelveInsight’s Refractory Multiple Myeloma pipeline report covers around 80+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Refractory Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Refractory Multiple Myeloma Pipeline Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Learn more about the emerging Refractory Multiple Myeloma Pipeline Therapies @ Refractory Multiple Myeloma Clinical Trials Assessment

 

Scope of the Refractory Multiple Myeloma Pipeline Report

  • Coverage- Global
  • Refractory Multiple Myeloma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Refractory Multiple Myeloma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Refractory Multiple Myeloma Companies- NexImmune, Amgen, AbbVie, Allogene Therapeutics, Precision Biosciences, Takeda Oncology, ORIC Pharmaceuticals, Ionis Pharmaceuticals, Cellectis S.A., YZY Biopharma, Janssen Research & Development, Bristol Myers Squibb, Lava Therapeutics, Prelude Therapeutics, and others.
  • Refractory Multiple Myeloma Pipeline Therapies- Venetoclax, Dexamethasone, Carfilzomib, Elotuzumab, Thalidomide, Cyclophosphamide, and others.

 

Dive deep into rich insights for new drugs for Refractory Multiple Myeloma treatment, Visit @ Refractory Multiple Myeloma Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Refractory Multiple Myeloma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Refractory Multiple Myeloma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name : Company name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase I/II)
  11. NEXI 002: NexImmune
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. ABBV 453: AbbVie
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name : Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Refractory Multiple Myeloma Key Companies
  21. Refractory Multiple Myeloma Key Products
  22. Refractory Multiple Myeloma- Unmet Needs
  23. Refractory Multiple Myeloma- Market Drivers and Barriers
  24. Refractory Multiple Myeloma- Future Perspectives and Conclusion
  25. Refractory Multiple Myeloma Analyst Views
  26. Refractory Multiple Myeloma Key Companies
  27. Appendix

 

For further information on the Refractory Multiple Myeloma pipeline therapeutics, reach out @ Refractory Multiple Myeloma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/farbers-disease-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Refractory Multiple Myeloma Pipeline, FDA Approvals, Clinical Trials Development, Companies 2023 | NexImmune, Amgen, AbbVie, Allogene Therapeutics, Precision Biosciences, Takeda, and others.

CAR-T Therapy Pipeline, FDA Approvals, Clinical Trials Development, Companies 2023 | CARsgen, CASI Pharmaceuticals, Tessa Therapeutics, Cartesian Therapeutics, Gracell Bio, Aurora BioPharma, and other

DelveInsight’s, “CAR-T Therapy Pipeline Insight 2023” report provides comprehensive insights about 200+ companies and 252+ pipeline drugs in the CAR-T Therapy pipeline landscape. It covers the CAR-T Therapy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CAR-T Therapy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the CAR-T Therapy Pipeline Report

  • DelveInsight’s CAR-T Therapy pipeline report depicts a robust space with 200+ active players working to develop 252+ pipeline therapies for CAR-T Therapy treatment.
  • The leading companies working in the CAR-T Therapy Market include CARsgen, CASI Pharmaceuticals, Tessa Therapeutics, Cartesian Therapeutics, Gracell Bio, Aurora BioPharma, Carsgen Therapeutics, Autolus Limited, CRISPR Therapeutics, Allogene Therapeutics, Verismo Therapeutics, Arcellx, Nexcella, JW Therapeutics, Janssen Pharmaceuticals, Chongqing Precision Biotech, CoImmune, Inc., Mustang Bio, Novartis Pharmaceuticals, Shanghai Unicar-Therapy Bio-medicine Technology, Sotio Biotech Inc., Beam Therapeutics, AbCLon, Nanjing IASO Biotherapeutics, Autolus, Beijing Immunochina Medical Science and Technology, Carsgen Therapeutics, Orgenesis, IN8Bio, Oxford BioMedica, and others.
  • Promising CAR-T Therapy Pipeline Therapies in the various stages of development include Glofitamab, Obinutuzumab, Tocilizumab, Pembrolizumab, C-CAR066, Mosunetuzumab, Polatuzumab, and others.
  • December 2023: Novartis Pharmaceuticals announced a study of Phase 2 clinical trials for PHE885. A Phase 2 Study of PHE885, B-cell Maturation Antigen (BCMA)- Directed CAR-T Cells in Adult Participants With Relapsed and Refractory Multiple Myeloma.
  • December 2023: Allogene Therapeutics announced a study of Phase 1 clinical trials for ALLO-501, ALLO-647, Fludarabine and Cyclophosphamide. The purpose of the ALPHA study is to assess the safety, efficacy, cell kinetics and immunogenicity of ALLO-501 in adults with relapsed or refractory large B-cell lymphoma or follicular lymphoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647.
  • November 2023: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd announced a study of Phase 1 clinical trials for CD19 CAR-T cells. This study will evaluates the safety and efficacy of Chimeric antigen receptor T cells (CAR-T) in treating central nervous system B-cell acute lymphocytic leukemia.
  • November 2023: Chongqing Precision Biotech Co., Ltd announced a study of Phase 1 clinical trials for CEA CAR-T cells. This trial is an open-label, single-arm clinical study. The main purpose is to verify the safety and efficacy of CAR-T cell preparations in the treatment of CEA-positive advanced malignant tumors, and to obtain the recommended dose and infusion scheme of CAR-T cell preparations for the treatment of patients with CEA-positive advanced malignant tumors.

 

Request a sample and discover the recent advances in CAR-T Therapy Treatment Drugs @ CAR-T Therapy Pipeline Report

 

In the CAR-T Therapy pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, CAR-T Therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

CAR-T Therapy Overview

Chimeric Antigen Receptors (CARs), also known as chimeric immunoreceptors, chimeric T cell receptors or artificial T cell receptors—are receptor proteins that have been engineered to give T cells the new ability to target a specific antigen. The receptors are chimeric in that they combine both antigen-binding and T cell activating functions into a single receptor.

 

Find out more about CAR-T Therapy Treatment Drugs @ Drugs for CAR-T Therapy Treatment

 

CAR-T Therapy Emerging Drugs Profile

  • CT053: Carsgen Therapeutics
  • Descartes-08: Cartesian Therapeutics
  • ALLO-501A: Allogene Therapeutics
  • CTX110: CRISPR Therapeutics
  • IMPT 314: ImmPACT Bio
  • ALLO-715: Allogene Therapeutics

 

CAR-T Therapy Pipeline Therapeutics Assessment

There are approx. 200+ key companies which are developing the therapies for CAR-T Therapy. The CAR-T Therapy companies which have their CAR-T Therapy drug candidates in the most advanced stage, i.e. Registered include, Carsgen Therapeutics.

 

DelveInsight’s CAR-T Therapy pipeline report covers around 252+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

CAR-T Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

CAR-T Therapy Pipeline Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Learn more about the emerging CAR-T Therapy Pipeline Therapies @ CAR-T Therapy Clinical Trials Assessment

 

Scope of the CAR-T Therapy Pipeline Report

  • Coverage- Global
  • CAR-T Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • CAR-T Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • CAR-T Therapy Companies- CARsgen, CASI Pharmaceuticals, Tessa Therapeutics, Cartesian Therapeutics, Gracell Bio, Aurora BioPharma, Carsgen Therapeutics, Autolus Limited, CRISPR Therapeutics, Allogene Therapeutics, Verismo Therapeutics, Arcellx, Nexcella, JW Therapeutics, Janssen Pharmaceuticals, Chongqing Precision Biotech, CoImmune, Inc., Mustang Bio, Novartis Pharmaceuticals, Shanghai Unicar-Therapy Bio-medicine Technology, Sotio Biotech Inc., Beam Therapeutics, AbCLon, Nanjing IASO Biotherapeutics, Autolus, Beijing Immunochina Medical Science and Technology, Carsgen Therapeutics, Orgenesis, IN8Bio, Oxford BioMedica, and others.
  • CAR-T Therapy Pipeline Therapies- Glofitamab, Obinutuzumab, Tocilizumab, Pembrolizumab, C-CAR066, Mosunetuzumab, Polatuzumab, and others.

 

Dive deep into rich insights for new drugs for CAR-T Therapy treatment, Visit @ CAR-T Therapy Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. CAR-T Therapy: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. CAR-T Therapy– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Registered)
  8. CT053: Carsgen Therapeutics
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Descartes-08: Cartesian Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. ALLO-715: Allogene Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. ACLX 003: Arcellx
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. CAR-T Therapy Key Companies
  21. CAR-T Therapy Key Products
  22. CAR-T Therapy- Unmet Needs
  23. CAR-T Therapy- Market Drivers and Barriers
  24. CAR-T Therapy- Future Perspectives and Conclusion
  25. CAR-T Therapy Analyst Views
  26. CAR-T Therapy Key Companies
  27. Appendix

 

For further information on the CAR-T Therapy pipeline therapeutics, reach out @ CAR-T Therapy Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/fabry-disease-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: CAR-T Therapy Pipeline, FDA Approvals, Clinical Trials Development, Companies 2023 | CARsgen, CASI Pharmaceuticals, Tessa Therapeutics, Cartesian Therapeutics, Gracell Bio, Aurora BioPharma, and other